Synchronous and Metachronous Metastatic Breast Cancer with Different Histology and Opposite Immunophenotype Treated with Combination of Chemotherapy Anti-Her2 and Endocrine Therapy: A Case Report

摘要

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.